Latest Quarterly Financial Summary
For Q2 2026 (H1 2026 reported on July 30, 2026), dsm-firmenich delivered solid results characterized by accelerating volume-led momentum.Like-for-like (LFL) sales growth reached 6% in Q2, accelerating from 4% in Q1, bringing total H1 2026 revenue to €4,664 million.Growth was driven entirely by volume expansion (+6%), while pricing remained stable at 0%. Adjusted EBITDA for Q2 reached €466 million, up 10% LFL, with sequential Adjusted EBITDA margin expanding by 40 basis points to 19.5% despite facing foreign exchange headwinds.
Segment & Regional Breakdown
Segment Revenue & Business Summary
- Perfumery & Beauty (~38% of revenue): Focuses on fine fragrances, consumer fragrances, and personal care ingredients. Generated 7% LFL sales growth in Q2 2026, driven by strong double-digit growth in Fine Fragrances and high-single-digit expansion in Consumer Fragrances.
- Taste, Texture & Health (~26% of revenue): Provides food and beverage solutions, including dairy, baking, and beverage ingredients. Achieved 6% LFL growth in Q2 2026 (accelerated from 2% in Q1), supported by revenue synergies and expanding adoption of Bovaer®.
- Health, Nutrition & Care (~22% of revenue): Provides active ingredients for dietary supplements, pharmaceutical solutions, and infant nutrition. Delivered 4% LFL sales growth in Q2 2026, supported by strong demand for Human Milk Oligosaccharides (HMOs) and Biomedical products.
- Animal Nutrition & Health (~14% of revenue): Focuses on animal feed additives, premixes, and veterinary nutrition solutions.
Regional Breakdown & Geographic Overview
- Europe, Middle East & Africa (EMEA): Represents approximately 35% of total sales. The region showed resilient momentum, with June accelerating following the easing of regional customer sentiment concerns.
- North America: Accounts for roughly 30% of sales. Strong performance in Perfumery and Fine Fragrances was partially offset by lingering soft consumer demand in Dietary Supplements.
- Asia-Pacific (APAC): Generates around 25% of sales. Sustained high demand for beverage and dairy applications in China and Southeast Asia supported regional performance.
- Latin America: Represents around 10% of total revenue. Showed solid growth driven by agricultural solutions and personal care ingredient demand.
Recent Quarterly Shifts, Key Metrics & Future Outlook
During Q2 2026, foreign exchange movements created a significant headwind, dragging down H1 sales by 4% and Adjusted EBITDA by 7% (amounting to a €60 million FX impact in H1). However, core operational metrics improved, with Core Adjusted EPS rising 14% to €1.84 in H1 2026 and Core Adjusted ROCE increasing to 11.6%.
For the upcoming quarters, key observation points include whether the June volume surge reflects sustained end-market demand versus short-term customer inventory restocking. Additionally, foreign exchange headwinds are expected to moderate to approximately €25 million in H2. Full-year 2026 guidance remains unchanged, targeting organic sales growth at the upper end of 2-4% and an Adjusted EBITDA margin near 20%.
Three-Month Stock Price Performance & Market Drivers
Over the past three months (June to August 2026), dsm-firmenich’s stock (AMS: DSFIR) experienced a major upward rally, surging approximately +34% from around €70.86 in early June to €95.30 by late August 2026.
The main driver behind this stock appreciation was the Q2 2026 financial release on July 30, 2026, where the stock spiked over +13% in a single day.The market reacted positively to the accelerated 6% LFL growth, strong volume beat over consensus, expanding EBITDA margins, and management’s progress on merger synergy capture.
Sources
- https://www.dsm-firmenich.com/corporate/investors.html
- https://www.morningstar.com/stocks/xams/dsfir/quote
- https://www.investing.com/news/company-news/dsmfirmenich-h1-2026-slides-margins-expand-synergies-on-track-93CH-4822643
- https://www.trivano.com/persbericht/dsm-firmenich-q1-2026-trading-update-727358.html
Back to DSM